Sarcoma Drugs Global Market Report 2024

The sarcoma drugs market has grown strongly in recent years. It will grow from $1.28 billion in 2023 to $1.39 billion in 2024 at a compound annual growth rate (CAGR) of 8.7%.The expansion observed in the historical period can be ascribed to factors such as the development of healthcare infrastructure, the establishment of treatment guidelines, the influence of patient advocacy groups, advancements in diagnosis methods, and a heightened awareness of the respective diseases.

The sarcoma drugs market is expected to see strong growth in the next few years. It will grow to $1.97 billion in 2028 at a compound annual growth rate (CAGR) of 9.1%. The anticipated growth in the forecast period is linked to various factors, including the increasing demand for novel therapies, rising investments in healthcare, the emergence of precision medicine, advancements in clinical trials and discoveries, and ongoing research and development activities. Key trends expected during this period encompass advancements in immunotherapy, the adoption of combination therapies, initiatives for early diagnosis, ongoing biomarker research, and a growing emphasis on a patient-centric approach.

The escalating incidence of soft tissue sarcoma is expected to drive the growth of the sarcoma drugs market. Soft tissue sarcoma, a form of cancer originating in the body's soft tissues such as muscles, fat, tendons, lymph, and nerves, is effectively addressed by sarcoma drugs in the healthcare industry. These drugs play a crucial role in treating both bone and soft tissue sarcoma by targeting and disrupting the growth of cancer cells. As reported by the American Cancer Society in January 2023, approximately 13,400 new cases of soft tissue sarcomas are anticipated to be diagnosed in the United States, with an estimated 5,140 deaths attributed to this form of cancer in the same year. Consequently, the increasing prevalence of soft tissue sarcoma is a significant factor propelling the growth of the sarcoma drugs market.

The growing demand for chemotherapy is poised to contribute to the expansion of the sarcoma drugs market. Chemotherapy, a medical intervention involving the use of drugs to kill or inhibit the growth of rapidly dividing cancer cells, finds extensive application in the treatment of sarcoma. Sarcoma drugs utilized in chemotherapy play diverse roles, including tumor reduction, adjuvant treatment, metastasis control, combination therapy, palliative care, risk reduction of recurrence, and enhancement of survival rates. A report from Healthcare IT News in February 2022, citing the Union for International Cancer Control (UICC), predicted a rise in the demand for cancer chemotherapy from 10 million to 15 million by 2040. This surge in demand underscores the increasing reliance on chemotherapy, thereby driving the growth of the sarcoma drugs market.

The development of new and innovative therapies has emerged as a prominent trend gaining traction in the sarcoma drugs market, with major companies actively pursuing advancements to strengthen their market positions. A notable example is Aadi Bioscience, a US-based biopharmaceutical company, which introduced Fyarro in November 2021. Fyarro, a sirolimus protein-bound particle, represents a novel cancer medication designed for the treatment of an ultrarare and aggressive form of sarcoma known as advanced perivascular epithelioid cell tumor (PEComa). Aadi Bioscience envisions Fyarro becoming a standard care option for patients with PEComa, emphasizing its potential impact on advancing treatment options for this specific sarcoma.

Major companies in the sarcoma drugs market are strategically focusing on obtaining product approvals to drive market revenues. Genentech Inc., a US-based biotechnology company, received FDA approval in December 2022 for tecentriq (atezolizumab), a monoclonal antibody. Tecentriq is indicated for the treatment of adult patients with advanced alveolar soft part sarcoma (ASPS), marking the first-ever approved treatment for this uncommon soft tissue sarcoma. The medication targets the PD-1/PD-L1 pathway, blocking immune system suppression and offering a promising therapeutic option for individuals diagnosed with ASPS.

In March 2023, Pfizer Inc., a prominent US-based pharmaceutical company, completed the acquisition of Seagen Inc. for $43 billion. This strategic move positions Pfizer Inc. as a leader in cancer care and doubles the size of its oncology portfolio. Seagen Inc., a biotechnology company, is known for its focus on developing new cancer therapies. The acquisition underscores Pfizer's commitment to advancing its capabilities in the oncology space through strategic partnerships and expansion of its product offerings.

Major companies operating in the sarcoma drugs market report are Amgen Inc., Bayer AG, Eisai Co. Ltd., Eli Lilly and Company, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Novartis AG, Pfizer Inc., AgonOX Inc., Daiichi Sankyo Company Limited, Merck & Co. Inc., Abbott Laboratories, AbbVie Inc., Amneal Pharmaceuticals LLC, Pharma Mar SA, Bristol-Myers Squibb Company, Fresenius Kabi AG, Ipsen SA, Radiopharm Theranostics, Baxter Healthcare Corporation, Akeso Biopharma, AstraZeneca plc, BeiGene Ltd., Bausch Health Companies Inc., Celgene Corporation, Shenzhen Chipscreen Biosciences Co. Ltd., Teva Pharmaceuticals Industries Ltd., Monopar Therapeutics Inc., Incyte Corporation, Sanofi SA, Takeda Pharmaceutical Company Limited, Roche Holding AG.

North America was the largest region in the sarcoma drugs market in 2023. The regions covered in the sarcoma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sarcoma drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary treatment modalities for sarcoma drugs include chemotherapy and targeted therapy. Chemotherapy, a widely employed cancer treatment, utilizes drugs to combat cancer cells. The range of disease indications for sarcoma drugs encompasses malignant bone tumors and soft tissue sarcoma, with distribution facilitated through channels such as hospital pharmacies, retail pharmacies, online pharmacies, and other relevant outlets.

The sarcoma drugs market research report provides sarcoma drugs market statistics, including sarcoma drugs industry global market size, regional shares, competitors with a sarcoma drugs market share, detailed sarcoma drugs market segments, market trends and opportunities, and any further data you may need to thrive in the sarcoma drugs industry. This sarcoma drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The sarcoma drug market consists of sales of atezolizumab, cosmegen, dactinomycin, doxorubicin hydrochloride, eribulin mesylate, fyarro, and gleevec. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.